Roche's phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

GlobeNewswire
2025.10.18 06:02
portai
I'm PortAI, I can summarize articles.

巴塞爾，2025 年 10 月 18 日- 羅氏（SIX: RO, ROG. OTCQX: RHHBY）今天宣佈了 III 期 evERA 乳腺癌研究的積極結果。數據顯示，giredestrant 與依維莫司聯合使用顯著降低了疾病進展或死亡的風險（無進展生存期）

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.